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Abstract 
This report describes formation of a full-thickness macular hole subsequent to an 
injection of bevacizumab for the treatment of neovascular AMD. This complication may 
be caused by focal tractional forces on the retinal surface due to either vitreous 
incarceration at the injection site or contraction of the choroidal neovascularization 
membrane. Alternatively, it may be due to a toxic effect of bevacizumab on a previously 
compromised retina. 
 
Introduction 
Age-related macular degeneration (AMD) is the leading cause of irreversible severe 
central visual acuity loss in people over 50 years of age in the developed world [1]. Anti-
angiogenic drugs have become increasingly popular for the treatment of choroidal 
neovascularization (CNV) that occurs in a variety of conditions, such as AMD, diabetic 
retinopathy, retinal venous occlusive disease, high myopia, trauma, and others [2]. 
Current research has focused on anti-vascular endothelial growth factor (VEGF) drugs, 
most notably ranibizumab (Lucentis
TM), which has been approved by the FDA for use in  
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ocular disease. Bevacizumab (Avastin
TM) is a recombinant humanized monoclonal 
antibody that binds VEGF and inhibits its interaction with endothelial receptors. Due to 
its relatively lower cost, it has been widely used ‘off-label’ in recent years for the 
aforementioned indications [3]. 
There are no large-scale, long-term randomized controlled studies on the safety and 
efficacy of bevacizumab [3], although several studies have focused on its potential 
complications and adverse effects. Wong et al. [2] reported a very low rate of ocular 
adverse effects after intravitreal bevacizumab injection, such as retinal pigment 
epithelium (RPE) tears, retinal ischemia, ocular irritation and cataract progression. Other 
potential adverse effects are very rare, and include retinal tears, retinal detachment, 
endophthalmitis and intraocular inflammation. Macular hole formation after intravitreal 
injections are very rare and have been described only in a small number of case reports 
[4–7]. 
There is a general consensus that adverse effects after intravitreal injections are more 
likely caused by the injection rather than by the administered medication. A number of 
studies have shown that the most common adverse effect related to a bevacizumab 
injection is the formation of RPE tears which occur in 0.8–2.9% of cases and mostly in 
eyes with neovascular AMD and pigment epithelium detachment (PED) [2, 3, 8]. It 
should be noted, however, that such tears have also been reported to occur following 
photodynamic therapy as well as spontaneously [9]. 
We present a patient with neovascular AMD and PED who developed a full-thickness 
macular hole after an intravitreal injection of bevacizumab in his right eye. 
Case Report 
An 86-year-old man was referred to our clinic for treatment of subfoveal CNV and PED in his right 
eye due to neovascular AMD. His left eye had previously suffered from neovascular AMD, and its visual 
acuity was reduced to bare light perception due to large subretinal and choroidal hemorrhages following 
photodynamic therapy treatment for CNV several years earlier. His right eye had been previously 
treated 6 times with intravitreal bevacizumab after which there were no untoward sequelae. Upon 
presentation, the visual acuity of the affected eye was 20/40. The initial fluorescein angiographic and 
optical coherence tomographic (OCT) images (fig. 1) demonstrate early subfoveal hyperfluorescence 
with staining in the later phases, confirming a still active CNV, retinal pigment elevation, the presence 
of subretinal fluid and an area of hyper-reflectivity. It is important to note that OCT demonstrated the 
presence of posterior vitreous detachment. After discussing the available treatment options and their 
potential benefits and side effects, the patient gave his written informed consent to undergo the 
recommended intravitreal bevacizumab injection (1.25 mg/0.05 ml). One month after the injection, his 
visual acuity had worsened to 20/60. Fluorescein angiography demonstrated leakage from the partially 
fibrotic subfoveal CNV, as well as a round area of hyperfluorescence compatible with a full-thickness 
macular hole (fig. 2a, b). OCT demonstrated persistence of the PED, a small amount of subfoveal 
subretinal fluid, and a new grade 4 macular hole (fig. 2c). The possibility of surgical repair of the 
macular hole was discussed, and the patient chose not to undergo any operation in his only functional 
eye. 
Discussion 
We report a patient with neovascular AMD and PED who developed a full-thickness 
macular hole following the 7th intravitreal bevacizumab injection to his right eye. Our 
review of the literature revealed only 3 publications describing a similar occurrence. The 
first described a patient with neovascular AMD with subfoveal CNV and vitreomacular 
traction who developed a stage 2 macular hole [5]. The second described a patient with  
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myopic CNV who developed a retinal detachment with a macular hole [6]. The third 
described a patient with severe diabetic proliferative retinopathy who developed a retinal 
detachment with a macular hole [7]. To the best of our knowledge, this is the first 
description of a macular hole forming subsequent to bevacizumab injection for the 
treatment of neovascular AMD. 
Several mechanisms may have caused the macular hole in our patient. Contraction of 
the prefoveal vitreous cortex results in focal traction which may cause macular hole 
formation, as hypothesized by Gass [10]. Vitreous incarceration at the site of injection 
may have caused such traction. However, as posterior vitreous detachment was 
demonstrated in the affected eye, tractional forces causing the formation of the macular 
hole are less likely in this case. The macular hole may be attributed to the pharmacological 
effect of bevacizumab on the CNV, since it can cause contraction resulting in traction on 
the retinal surface. Alternatively, it is possible that the macular hole was caused by toxicity 
of bevacizumab on a previously compromised retina. This explanation is least likely as 
several studies found no toxic effect of bevacizumab on the retina and RPE, even after 
repeated injections [11, 12]. Another possible explanation is that the macular hole is the 
result of progressive retinal and RPE atrophy in a patient with AMD. 
In conclusion, macular holes may be a rare adverse effect of bevacizumab injection, 
whether mechanical or toxic. Patients need to be warned about this potential 
complication, and it should be included in the differential diagnosis when visual acuity 
does not improve or if it deteriorates after treatment with bevacizumab. 
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Fig. 1. Initial fluorescein angiograph demonstrating early subfoveal hyperfluorescence (a) with 
staining in the later phases (b), confirming a still active CNV and retinal pigment elevation, the 
presence of subretinal fluid and an area of hyperreflectivity. Initial optical coherence tomography 
demonstrating PED and no macular hole (c). 
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Fig. 2. Fluorescein angiograph at one month after an intravitreal bevacizumab injection into the eye 
described in figure 1, demonstrating early subfoveal hyperfluorescence (a) and in later phases dye 
leakage consistent with a partially fibrotic subfoveal CNV, and an area of hyperfluorescence compatible 
with a full-thickness macular hole (arrow) (b). c OCT at one month after intravitreal bevacizumab 
injection demonstrating persistence of the PED and a small amount of subfoveal subretinal fluid, as well 
as a new grade 4 macular hole. 
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